2026 Global: Biologics Contract Development Market-Competitive Review (2032) report
Description
The 2026 Global: Biologics Contract Development Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Lonza remains a dominant force in the biologics contract development and manufacturing market, with its headquarters in Basel, Switzerland, and a global network that supports development and GMP manufacturing for monoclonal antibodies, enzymes, and viral vectors. Samsung Biologics, headquartered in Incheon, South Korea, operates large-scale mammalian-cell production facilities designed to accelerate clinical and commercial programs for leading biopharma partners. WuXi Biologics, based in Shanghai, China, offers end-to-end development and manufacturing services across discovery through commercial supply, including plasmid DNA, cell lines, and complex biologics. Thermo Fisher Scientific, through its Patheon Biologics division, is headquartered in Waltham, United States, delivering integrated early development, clinical manufacturing, and scale-up for biologics within a broader life sciences portfolio. Catalent, headquartered in Somerset, New Jersey, United States, provides biologics CDMO services from cell line development to fill-finish, supported by a global manufacturing footprint and analytical platforms.
Fujifilm Diosynth Biotechnologies, headquartered in Morrisville, North Carolina, United States, offers both microbial and mammalian production platforms, enabling rapid scale-up from development through late-stage manufacturing across multiple biosystems. Boehringer Ingelheim, headquartered in Ingelheim am Rhein, Germany, maintains extensive biologics development and production capabilities, collaborating with partners to bring novel monoclonal antibodies and fusion proteins to market. Rentschler Biotechnologie, based in Laupheim, Germany, focuses on customer-driven mammalian cell culture, large-scale manufacturing, and process development for complex biologics. Syngene International, headquartered in Bengaluru, India, provides integrated biologics development services—from gene-to-cell-line development to GMP manufacturing and fill-finish—supported by a growing network of clinical and commercial production sites.
Biocon Biologics, headquartered in Bengaluru, India, offers end-to-end biologics development and manufacturing services, including biosimilar program development, process optimization, and commercial manufacturing, with multi-site capabilities and global partnerships. It collaborates with leading global biotech and pharmaceutical companies to optimize expression constructs, cell line development, analytics, and scalable purification processes. Biocon's facilities in India and elsewhere provide end-to-end support—from early-stage development through scale-up and commercial production—across therapeutic areas such as monoclonal antibodies, fusion proteins, antibody-drug conjugates, and peptide-based therapeutics. Biocon Biologics emphasizes quality, regulatory readiness, and supply chain resilience, leveraging digital quality systems, real-time release testing, and a global distribution network to meet diverse regulatory requirements in the Americas, Europe, and Asia-Pacific. The organization also pursues biosimilar programs that address lifecycle management, market access, and affordability, working with partners to navigate patent landscapes, comparative analytical studies, and pharmacovigilance obligations. As the biologics CDMO market consolidates, Biocon Biologics positions itself as an agile, cost-competitive partner capable of delivering development speed and reliable manufacturing at commercial scales. With ongoing investments in manufacturing capacity, including expansion of downstream purification and fill-finish capabilities, the company aims to support complex biologics pipelines from discovery through commercial launch, while maintaining rigorous quality standards and patient safety as primary priorities for patients worldwide.
Lonza remains a dominant force in the biologics contract development and manufacturing market, with its headquarters in Basel, Switzerland, and a global network that supports development and GMP manufacturing for monoclonal antibodies, enzymes, and viral vectors. Samsung Biologics, headquartered in Incheon, South Korea, operates large-scale mammalian-cell production facilities designed to accelerate clinical and commercial programs for leading biopharma partners. WuXi Biologics, based in Shanghai, China, offers end-to-end development and manufacturing services across discovery through commercial supply, including plasmid DNA, cell lines, and complex biologics. Thermo Fisher Scientific, through its Patheon Biologics division, is headquartered in Waltham, United States, delivering integrated early development, clinical manufacturing, and scale-up for biologics within a broader life sciences portfolio. Catalent, headquartered in Somerset, New Jersey, United States, provides biologics CDMO services from cell line development to fill-finish, supported by a global manufacturing footprint and analytical platforms.
Fujifilm Diosynth Biotechnologies, headquartered in Morrisville, North Carolina, United States, offers both microbial and mammalian production platforms, enabling rapid scale-up from development through late-stage manufacturing across multiple biosystems. Boehringer Ingelheim, headquartered in Ingelheim am Rhein, Germany, maintains extensive biologics development and production capabilities, collaborating with partners to bring novel monoclonal antibodies and fusion proteins to market. Rentschler Biotechnologie, based in Laupheim, Germany, focuses on customer-driven mammalian cell culture, large-scale manufacturing, and process development for complex biologics. Syngene International, headquartered in Bengaluru, India, provides integrated biologics development services—from gene-to-cell-line development to GMP manufacturing and fill-finish—supported by a growing network of clinical and commercial production sites.
Biocon Biologics, headquartered in Bengaluru, India, offers end-to-end biologics development and manufacturing services, including biosimilar program development, process optimization, and commercial manufacturing, with multi-site capabilities and global partnerships. It collaborates with leading global biotech and pharmaceutical companies to optimize expression constructs, cell line development, analytics, and scalable purification processes. Biocon's facilities in India and elsewhere provide end-to-end support—from early-stage development through scale-up and commercial production—across therapeutic areas such as monoclonal antibodies, fusion proteins, antibody-drug conjugates, and peptide-based therapeutics. Biocon Biologics emphasizes quality, regulatory readiness, and supply chain resilience, leveraging digital quality systems, real-time release testing, and a global distribution network to meet diverse regulatory requirements in the Americas, Europe, and Asia-Pacific. The organization also pursues biosimilar programs that address lifecycle management, market access, and affordability, working with partners to navigate patent landscapes, comparative analytical studies, and pharmacovigilance obligations. As the biologics CDMO market consolidates, Biocon Biologics positions itself as an agile, cost-competitive partner capable of delivering development speed and reliable manufacturing at commercial scales. With ongoing investments in manufacturing capacity, including expansion of downstream purification and fill-finish capabilities, the company aims to support complex biologics pipelines from discovery through commercial launch, while maintaining rigorous quality standards and patient safety as primary priorities for patients worldwide.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
